In prognosis analysis of GSE20865 cohort, the data affirmed a better OS and RFS rate in breast cancer patients with elevated MTF1 expression levels (Figures 9(c) and 9(d), p < 0.05). This evidence concerns the gene MTF1 and breast carcinoma.